211 related articles for article (PubMed ID: 19431954)
1. Severe neonatal renal failure after maternal use of angiotensin II type I receptor antagonists.
Sinelli MT; Cattarelli D; Cortinovis S; Maroccolo D; Chirico G
Pediatr Med Chir; 2008; 30(6):306-8. PubMed ID: 19431954
[TBL] [Abstract][Full Text] [Related]
2. Fetal toxic effects of angiotensin II receptor antagonists: case report and follow-up after birth.
Bos-Thompson MA; Hillaire-Buys D; Muller F; Dechaud H; Mazurier E; Boulot P; Morin D
Ann Pharmacother; 2005 Jan; 39(1):157-61. PubMed ID: 15590878
[TBL] [Abstract][Full Text] [Related]
3. [Fetal toxicity of angiotensin-II-receptor inhibitors. Case report].
Roger N; Popovic I; Madelenat P; Mahieu-Caputo D
Gynecol Obstet Fertil; 2007 Jun; 35(6):556-60. PubMed ID: 17544313
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin II receptor antagonist treatment during pregnancy.
Alwan S; Polifka JE; Friedman JM
Birth Defects Res A Clin Mol Teratol; 2005 Feb; 73(2):123-30. PubMed ID: 15669052
[TBL] [Abstract][Full Text] [Related]
5. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
[TBL] [Abstract][Full Text] [Related]
6. Olmesartan associated with acute renal failure in a patient with bilateral renal artery stenosis.
Bavbek N; Kasapoglu B; Isik A; Kargili A; Kirbas I; Akcay A
Ren Fail; 2010; 32(9):1115-7. PubMed ID: 20863218
[TBL] [Abstract][Full Text] [Related]
7. [Transient renal failure in a newborn due angiotensin receptor II antagonist use during pregnancy: report of a case].
Hasbún H J; Valdés R E; San Martín O A; Catalán M J; Salinas Q S; Parra C M
Rev Med Chil; 2008 May; 136(5):624-30. PubMed ID: 18769811
[TBL] [Abstract][Full Text] [Related]
8. Increased renal echogenicity in a preterm neonate. Kidneys with tubular dysplasia due to exposure to candesartan during pregnancy.
Bald M; Holder M; Zieger M; Vochem M; Leichter HE
Pediatr Nephrol; 2005 Nov; 20(11):1664-5, 1666-8. PubMed ID: 16082550
[No Abstract] [Full Text] [Related]
9. Gestational therapy with an angiotensin II receptor antagonist and transient renal failure in a premature infant.
Bass JK; Faix RG
Am J Perinatol; 2006 Jul; 23(5):313-7. PubMed ID: 16799914
[TBL] [Abstract][Full Text] [Related]
10. Course and outcome of pregnancy after maternal exposure to angiotensin-II-receptor blockers--case report and review of the literature.
Enzensberger C; Eskef K; Schwarze A; Faas D; Axt-Fliedner R
Ultraschall Med; 2012 Oct; 33(5):493-6. PubMed ID: 21630188
[No Abstract] [Full Text] [Related]
11. Severe angioedema associated with olmesartan.
Vasquez JL; Jaramillo JC; Fernandez C; Enriquez A; Mielgo R
Ann Allergy Asthma Immunol; 2011 Sep; 107(3):285. PubMed ID: 21875552
[No Abstract] [Full Text] [Related]
12. Oligohydramnios and pulmonary hypoplasia: a case in which involvement of an angiotensin II receptor antagonist was suspected.
Kato K; Okuda M; Ishikawa H; Takahashi T; Hirahara F
J Obstet Gynaecol Res; 2008 Apr; 34(2):242-6. PubMed ID: 18412789
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin II receptor blocker induced fetopathy: 7 cases.
Hünseler C; Paneitz A; Friedrich D; Lindner U; Oberthuer A; Körber F; Schmitt K; Welzing L; Müller A; Herkenrath P; Hoppe B; Gortner L; Roth B; Kattner E; Schaible T
Klin Padiatr; 2011 Jan; 223(1):10-4. PubMed ID: 21271514
[TBL] [Abstract][Full Text] [Related]
14. Neonatal acute renal failure secondary to maternal exposure to telmisartan, angiotensin II receptor antagonist.
Pietrement C; Malot L; Santerne B; Roussel B; Motte J; Morville P
J Perinatol; 2003; 23(3):254-5. PubMed ID: 12732865
[TBL] [Abstract][Full Text] [Related]
15. Fetal toxicity of valsartan and possible reversible adverse side effects.
Berkane N; Carlier P; Verstraete L; Mathieu E; Heim N; Uzan S
Birth Defects Res A Clin Mol Teratol; 2004 Aug; 70(8):547-9. PubMed ID: 15329835
[TBL] [Abstract][Full Text] [Related]
16. Porphyria cutanea tarda induced by olmesartan.
Mas-Vidal A; Coto-Segura P; García-Varona A; Santos-Juanes J
J Eur Acad Dermatol Venereol; 2010 Aug; 24(8):977-8. PubMed ID: 20015057
[No Abstract] [Full Text] [Related]
17. [Treatment of arterial hypertension in the pregnant woman with labetalol. A propos of 24 cases].
Dubois D; Petitcolas J; Temperville B; Klepper A; Leboullenger P
J Gynecol Obstet Biol Reprod (Paris); 1984; 13(6):691-700. PubMed ID: 6520355
[TBL] [Abstract][Full Text] [Related]
18. Fetal and neonatal consequences of antenatal exposure to type 1 angiotensin II receptor-antagonists.
Vendemmia M; Garcia-Méric P; Rizzotti A; Boubred F; Lacroze V; Liprandi A; Simeoni U
J Matern Fetal Neonatal Med; 2005 Aug; 18(2):137-40. PubMed ID: 16203601
[TBL] [Abstract][Full Text] [Related]
19. Reversible acute fetal renal failure due to maternal exposure to angiotensin receptor blocker.
Celentano C; Prefumo F; di Vera E; Iannicco A; Gallo DP; Liberati M
Pediatr Nephrol; 2008 Feb; 23(2):333-4. PubMed ID: 17899204
[TBL] [Abstract][Full Text] [Related]
20. Neonatal anuria with maternal angiotensin-converting enzyme inhibition.
Rosa FW; Bosco LA; Graham CF; Milstien JB; Dreis M; Creamer J
Obstet Gynecol; 1989 Sep; 74(3 Pt 1):371-4. PubMed ID: 2761913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
